Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 20 Apr 2022 Results evaluating efficacy and long-term safety of triheptanoin in patients , not on a ketogenic diet, with drug-resistant seizures associated with Glucose Transporter Type 1 Deficiency Syndrome, published in the Epilepsia
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 The study has been Discontinued in Denmark. (End date: 2017-09-20).